Subclinical myocardial injury

1. eGFR has no effect on subclinical myocardial injury in humans (OR (95% CI): 1.10 (0.84–1.45)).

   “eGFR <45 (compared to ≥45) mL/min/1.73 m 2 was not associated with increased risk of SCMI (OR (95% CI): 1.10 (0.84–1.45)).”

   HumanseGFR <45 vs ≥45 mL/min/1.73 m2median follow-up of 18.4 yearsn = 6,057

   Kidney Function, Subclinical Myocardial Injury, and their Joint Association with Cardiovascular Mortality in the General Population

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

More on eGFR

1. Subclinical myocardial injury raises the risk of cardiovascular mortality in humans (HR 1.41, 95% CI 1.19–1.69).

   “HR for SCMI: 1.41, 95% CI: 1.19–1.69”

   Humansmedian follow-up of 18.8 yearsn = 6,079

   Association of METS-IR and Subclinical Myocardial Injury with Cardiovascular Mortality in U.S. Adults

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

2. Subclinical myocardial injury raises the risk of cardiovascular mortality in humans (HR (95% CI): 1.36 (1.16-1.60)).

   “SCMI (vs. no SCMI) and eGFR <45 (compared to ≥45) mL/min/1.73 m 2 were associated with an increased risk of CV mortality ((HR [95% CI]: 1.36 (1.16-1.60)”

   HumansSCMI vs no SCMImedian follow-up of 18.4 yearsn = 6,057

   Kidney Function, Subclinical Myocardial Injury, and their Joint Association with Cardiovascular Mortality in the General Population

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

1. METS-IR raises the risk of subclinical myocardial injury in humans (OR 1.20, 95% CI 1.13–1.28).

   “Each standard deviation increase in METS-IR was associated with greater odds of SCMI (OR: 1.20, 95% CI: 1.13–1.28, p<0.001).”

   Humansn = 6,079

   Association of METS-IR and Subclinical Myocardial Injury with Cardiovascular Mortality in U.S. Adults

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

More on METS-IR